A Case of Suspected Adverse Reactions to Sirolimus in the Treatment of Generalized Lymphatic Anomaly. (30th April 2019)

• Record Type: Journal Article
• Authors: Fujii, Takayuki; Shimono, Ryuichi; Tanaka, Aya; Katami, Hiroto
• Other Names: Romeo Carmelo Academic Editor.
• Is Part Of: Case reports in pediatrics. Volume 2019(2019)
• Publication Date: 2019-04-30
• Subjects: Pediatrics -- Periodicals; Pediatrics; Pediatrics; Electronic journals; Periodicals; Case Reports; Periodicals; Case Reports; Fulltext; Internet Resources; Periodicals; 618.92
• DOI: 10.1155/2019/3101357
• Languages: English
• ISSNs: 2090-6803

Abstract

Abstract : Generalized lymphatic anomaly (GLA) is characterized by diffuse or multicentric proliferation of dilated lymphatic vessels resembling common lymphatic malformation, and thoracic lesions can be related to a poor prognosis. Sirolimus, an inhibitor of the mammalian target of rapamycin, is effective against vascular anomalies with few severe adverse drug reactions. Here, we report the case of a patient with intractable hemothorax pleural effusion due to GLA who was treated with sirolimus and experienced disseminated intravascular coagulation. Although a standard treatment for GLA has not been established, pleural fluid might be reduced using the Kampo medicine Eppikajyutsuto.